MEDIGENE AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.505 EUR | -5.64% |
|
-21.61% | -1.31% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 98.25 | 86.46 | 70.37 | 49.62 | 37.46 | 36.97 | - | - |
| Enterprise Value (EV) 1 | 48.62 | 60.93 | 51.62 | 49.62 | 31.73 | 53.97 | 50.97 | 36.97 |
| P/E ratio | -4.94 x | -2.98 x | -6.99 x | -5.94 x | -2.31 x | -4.07 x | -2.69 x | -5.19 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 9.24 x | 9.88 x | 6.73 x | - | 6.21 x | 3.49 x | 5.32 x | 2.32 x |
| EV / Revenue | 4.57 x | 6.96 x | 4.93 x | - | 5.26 x | 5.09 x | 7.33 x | 2.32 x |
| EV / EBITDA | -2.73 x | -2.75 x | -7.87 x | - | -2.16 x | -4.57 x | -3.09 x | -2.82 x |
| EV / FCF | -2.72 x | -2.41 x | -4.74 x | - | - | -4.69 x | -2.82 x | - |
| FCF Yield | -36.7% | -41.5% | -21.1% | - | - | -21.3% | -35.5% | - |
| Price to Book | 1.2 x | 1.63 x | 1.57 x | - | 1.78 x | 5.79 x | -2.95 x | - |
| Nbr of stocks (in thousands) | 24,563 | 24,563 | 24,563 | 24,563 | 24,563 | 24,563 | - | - |
| Reference price 2 | 4.000 | 3.520 | 2.865 | 2.020 | 1.525 | 1.505 | 1.505 | 1.505 |
| Announcement Date | 3/26/20 | 3/25/21 | 3/23/22 | 3/29/23 | 3/28/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 10.63 | 8.749 | 10.46 | - | 6.034 | 10.6 | 6.95 | 15.9 |
| EBITDA 1 | -17.79 | -22.19 | -6.557 | - | -14.69 | -11.8 | -16.5 | -13.1 |
| EBIT 1 | -20.16 | -28.66 | -9.985 | - | -16.15 | -11.8 | -16.85 | -13.1 |
| Operating Margin | -189.63% | -327.63% | -95.43% | - | -267.63% | -111.32% | -242.45% | -82.39% |
| Earnings before Tax (EBT) 1 | -19.92 | -28.4 | -10.28 | - | -16.59 | -11.7 | -17.1 | -13 |
| Net income 1 | -19.96 | -28.88 | -9.983 | -8.33 | -16.18 | -11.7 | -17.1 | -13 |
| Net margin | -187.75% | -330.04% | -95.41% | - | -268.1% | -110.38% | -246.04% | -81.76% |
| EPS 2 | -0.8100 | -1.180 | -0.4100 | -0.3400 | -0.6600 | -0.3700 | -0.5600 | -0.2900 |
| Free Cash Flow 1 | -17.85 | -25.27 | -10.88 | - | - | -11.5 | -18.1 | - |
| FCF margin | -167.9% | -288.83% | -103.98% | - | - | -108.49% | -260.43% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/26/20 | 3/25/21 | 3/23/22 | 3/29/23 | 3/28/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|
| Net sales 1 | 1.55 | 3.064 | 2.97 | 4.15 | 6.85 |
| EBITDA | - | -6.62 | -8.066 | -7.2 | -4.6 |
| EBIT 1 | -4.116 | -7.372 | -8.777 | -7.2 | -4.6 |
| Operating Margin | -265.55% | -240.6% | -295.52% | -173.49% | -67.15% |
| Earnings before Tax (EBT) 1 | -4.255 | -7.699 | -8.893 | -7.1 | -4.5 |
| Net income 1 | -4.058 | -6.97 | -9.207 | -7.1 | -4.5 |
| Net margin | -261.81% | -227.48% | -310% | -171.08% | -65.69% |
| EPS 2 | -0.1700 | -0.2800 | -0.3800 | -0.2800 | -0.1200 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 8/17/23 | 8/17/23 | 3/28/24 | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 17 | 14 | - |
| Net Cash position 1 | 49.6 | 25.5 | 18.8 | - | 5.72 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -1.441 x | -0.8485 x | - |
| Free Cash Flow 1 | -17.9 | -25.3 | -10.9 | - | - | -11.5 | -18.1 | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 3.330 | 2.160 | 1.820 | - | 0.8600 | 0.2600 | -0.5100 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 1.43 | 0.48 | 0.13 | - | - | - | - | - |
| Capex / Sales | 13.43% | 5.53% | 1.19% | - | - | - | - | - |
| Announcement Date | 3/26/20 | 3/25/21 | 3/23/22 | 3/29/23 | 3/28/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.505
EUR
Average target price
2.675
EUR
Spread / Average Target
+77.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.31% | 39.46M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- MDG1 Stock
- Financials Medigene AG
